Free tool
FAERS Monitor: Acuvail
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022427 or its brand name (Acuvail, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.
Reports
4,504
Serious
2,551
57% of reports
Hospitalization
1,289
Death reported
262
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective491
- drug hypersensitivity301
- nausea253
- headache249
- pain237
- dyspnoea220
- fatigue219
- treatment failure205
- off label use179
- vomiting160
- diarrhoea149
- eye pain147
- product dose omission issue146
- eye irritation139
- dizziness126
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 70 |
| 2006 | 69 |
| 2007 | 64 |
| 2008 | 83 |
| 2009 | 106 |
| 2010 | 138 |
| 2011 | 180 |
| 2012 | 195 |
| 2013 | 78 |
| 2014 | 84 |
| 2015 | 103 |
| 2016 | 306 |
| 2017 | 232 |
| 2018 | 203 |
| 2019 | 278 |
| 2020 | 459 |
| 2021 | 222 |
| 2022 | 301 |
| 2023 | 365 |
| 2024 | 339 |
| 2025 | 345 |
| 2026 | 241 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,655 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 147 | 12.2 | 10.4 | 1,500 |
| treatment failureSignal | 205 | 11.6 | 10.1 | 1,974 |
| eye irritationSignal | 139 | 11.3 | 9.6 | 1,295 |
| drug hypersensitivitySignal | 301 | 7.3 | 6.5 | 1,635 |
| product dose omission issueSignal | 146 | 2.3 | 2.0 | 110 |
| headache | 249 | 1.9 | 1.6 | 100 |
| dyspnoea | 220 | 1.8 | 1.6 | 82 |
| pain | 237 | 1.8 | 1.6 | 86 |
| drug ineffective | 491 | 1.7 | 1.6 | 164 |
| vomiting | 160 | 1.6 | 1.4 | 35 |
| nausea | 253 | 1.5 | 1.3 | 42 |
| fatigue | 219 | 1.3 | 1.2 | 17 |
| dizziness | 126 | 1.2 | 1.0 | 3 |
| diarrhoea | 149 | 1.1 | 0.9 | 1 |
| off label use | 179 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.